Abstract Library

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,

#3815 Real-world observational study of somatostatin analogues and rescue medication use for neuroendocrine tumors in Canada

Introduction: Both octreotide long-acting release (OCT-LAR) and lanreotide autogel (LAN-ATG) are available in Canada for the management of neuroendocrine tumors (NETs). Patients can switch between SSAs due to effectiveness, adverse events (AEs), preference or reimbursement. For patients with functional disease, short acting SSAs can be used concomitantly as rescue medication to improve symptom control.

Conference:

Presenting Author:

Authors: Rayson D, Troesch M, Laforty C, Badin M, Liovas A,

Keywords: Neuroendocrine tumor, Somatostatin analogues, Lanreotide, Octreotide, SSA switch,

#3727 PREF-NET: A patient preference and experience study of lanreotide autogel (LAN) administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the UK

Introduction: The somatostatin analogue LAN is a common first-line treatment for NETs that can be given at home in a ready-to-use syringe every 4 weeks in the UK.

Conference:

Presenting Author: Khan M

Authors: Khan M, Davies L, Back M, Shah T, Pritchard D,

Keywords: patient participation, somatostatin analogues, injections, quality of life, value-based health care,

#3711 Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Homecare is an established delivery method utilised by the UK NHS. In the UK, patients with GEP-NETs on a stable dose of LAN can be trained for self or partner administration or can be administered by a homecare nurse. Both methods remove LAN related activity in an acute setting, negating costs to the provider. The National Tariff payment system is a set of prices to help the NHS deliver value to patients. The price, as set out in the 2022/23 National Tariff workbook, for a single professional follow-up endocrinology outpatient appointment is £101. The cost of this activity, as set out in the 2020/21 National Schedule of Costs, is £197. This represents a potential unreimbursed cost to the NHS of £96 per outpatient appointment.

Conference:

Presenting Author: Bolton R

Authors: Higgs K, Halpin C, Bolton R, Frankcom I,

Keywords: gastroenteropancreatic neuroendocrine tumor, lanreotide autogel, home administration, un-reimbursed costs,